Inhibiting ALKBH2/3 and other HR enzymes further sensitizes mIDH1 cells to PARP inhibitors, which induce tumor regression in IDH-mutant gliomas and cholangiocarcinomas [164–166]. Here, IDH1 is linked to cholangiocarcinoma.